Adverse Event reporting information can be found in footer

Request a Meeting

CORTIMENT® is indicated for the induction of remission in patients:

  • with mild to moderate Ulcerative Colitis (UC) when 5-ASA therapy is not sufficient1
  • with Active Microscopic Colitis (MC)1

MMX® technology enables targeted release of budesonide throughout the entire colon1,5-8



  • CORTIMENT® maintains the efficacy of corticosteroids in mild to moderate UC patients, while minimising systemic side effects and doesn’t need to be tapered1,6,8,10
  • CORTIMENT® is an effective add-on therapy to your patients’ current 5-ASA to treat mild to moderate UC flares and for the treatment of Active Microscopic Colitis1,9,15
  • CORTIMENT® has a simple once-daily dosing regimen for UC and Active MC, which could help support adherence: take one 9mg tablet once daily for 8 weeks with or without food and no dose tapering is required.1




  • Systemic steroids are frequently overused in UC and have a poor safety profile11-14
  1. Cortiment 9 mg, Prolonged Release Tablets. SmPC.
  2. Entocort CR 3 mg Capsules. SmPC.
  3. Budenofalk 3 mg Gastro-resistant Capsules. SmPC.
  4. Budenofalk 9 mg Gastro-resistant Granules. SmPC.
  5. Brunner M, et al. Br J Clin Pharmacol. 2006;61(1):31–8.
  6. Travis SPL, et al. Gut. 2014;63:433–41. doi:10.1136/gutjnl-2012-304258.
  7. Fiorino G, et al. Curr Med Chem. 2010;17(17):1851–7.
  8. Sandborn WJ, et al. Gastroenterology. 2012;143:1218–1226.
  9. Rubin D, et al. J Crohns Colitis. 2017;11(7):785–791.
  10. Danese S, et al. Intestinal Research. 2018;16(4):522–528.
  11. Danese S, et al. Aliment Pharmacol Ther. 2014;39:1095–1103.
  12. Prednisolone 5 mg Tablets. SmPC.
  13. Mahadevan U, et al. Clinics in Colon and Rectal Surgery.2004;17(1):7–19.
  14. Liu D, et al. Allergy, Asthma and Clinical Immunology.2013;9:30.
  15. National Institute for Health Care Excellence (NICE). Ulcerative Colitis:management guideline [NG130]. Published date: May 2019.Available from: accessed May 2019.

Job Code: UK-COR-2200001 - Date of preparation: January 2022


Our use of cookies

We use cookies (including third party cookies) to collect data while you use this website in order to make it work, keep it secure and comply with regulations. We’d also like your consent to use cookies so we can provide you with tailored content and advertising and analyse how you and other people use the website.

Select “On” to consent to our use of these cookies and continue to the website, or select “Off” to control which types of cookies we use. You can read more about cookies in our Privacy Policy.

Necessary cookies

Necessary cookies enable core functionality such as security, network management, and accessibility. You may disable these by changing your browser settings, but this may affect how the website functions.

Analytics cookies

We’d like to set Google Analytics cookies to help us to improve our website by collecting and reporting information on how you use it. The cookies collect information in away that does not directly identify anyone. For more information on how these cookies work, please see our Privacy Policy.